Singapore, May 19 -- CanSino Biologics Inc, based in China, has obtained clinical trial approval from the Badan Pengawas Obat danMakanan, Republik Indonesia to initiate a clinical trial for its InhaledTuberculosisVaccine(AdenovirusType5Vector) (the inhaled TB Booster).

Currently, the traditional Bacillus Calmette-Guerinvaccine (BCG vaccine), also the only available tuberculosis vaccine in the world, is typically administered at birth. Additionally, the BCG vaccine declines over time and cannot enhance vaccine protection through booster doses, resulting in limited protection for adults. To address this deficiency, the inhaled TB vaccine is the first generation of a globally innovative tuberculosis booster vaccine for the BCG vaccine.

The...